BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

Bio Reports

APAC's Peptide-Capacity Gamble

For most of pharmaceutical history, the hard part was finding a molecule that worked. The GLP-1 class inverted that logic. The science arrived first &mdash...

July 08, 2026 | Analysis

After the Rush: APAC's mRNA and Vaccine Capacity Hangover

In June 2022, South Korea had something it had wanted for two years: a COVID-19 vaccine of its own. SKYCovione, developed by SK bioscience with the U...

July 08, 2026 | Analysis

The Biosimilar Race: Factory to the World — or Stuck in the Copycat Economy?

In Songdo and Bengaluru, the numbers finally look like the ones the region was promised a decade ago. Celltrion closed 2025 with revenue above ₩4 trillio...

July 07, 2026 | Analysis

The Vein-to-Vein Problem: Can APAC's Cold Chain Carry Advanced Therapies?

The requirement: a chain that cannot break Key figures −150°C or colder — the temperature floor for most cell and gene therapies; som...

July 06, 2026 | Analysis

Vectors, Plasmids and the CGT Trap: APAC's Cell and Gene Therapy Ambitions Face an Upstream Bottleneck

THE GATE The choke point nobody puts on the slide Somewhere in the region this quarter, a cell-and-gene developer has everything the pitch deck promised....

July 03, 2026 | Analysis

Can APAC Build Radioligand Therapy Before the Atoms Decay?

Every dose of radioligand therapy is a countdown. The moment a batch of lutetium-177 leaves the reactor, it begins to fade — roughly half its therape...

July 02, 2026 | Analysis

The Great Biopharma Reset: 50 Developments That Changed Everything in H1 2026

For three years the biotechnology industry waited for a turn. The first half of 2026 delivered one — and then several more in quick succession. In si...

June 30, 2026 | Analysis

Beyond the Obvious Giant: Where APAC's Clinical Trials Go Next

For most of the last decade, the strategic case for running Asia-Pacific clinical trials could be summarised in a single word: China. A vast, treatment-n...

June 29, 2026 | Analysis

The Frontier That Won’t Quite Arrive

Ask the region’s clinical-operations leaders whether decentralised and hybrid trials are the future, and the answer is almost unanimous. Surveys keep...

June 26, 2026 | Analysis

Metabolon Delivers Landmark Metabolomics Dataset to Advance Rare Disease Research with Genomics England

Metabolon, Inc., the global leader in metabolomics solutions advancing life science research, diagnostics, therapeutics, and precision medicine, announced ...

June 26, 2026 | News

Vendor to Co-Innovator — or Bring It In-House? The CDMO Relationship Rewires

For two decades the contract development and manufacturing organisation occupied a comfortable, clearly understood place in the biopharma value chain. The ...

June 25, 2026 | Analysis

Security at What Cost? APAC and the Great Supply-Chain Reordering

For the better part of two decades, the global pharmaceutical supply chain ran on a simple, unsentimental bargain: make the chemistry where it is cheapest,...

June 24, 2026 | Analysis

Europe Greenlights BRAFTOVI, Cetuximab and FOLFOX Regimen for Previously Untreated BRAF-Mutant mCRC

uropean approval is based on results from the Phase 3 BREAKWATER trial, which demonstrated that encorafenib in combination with cetuximab and mFOLFOX6 de...

June 24, 2026 | News

Billions on Bioconjugation: Is APAC Building the Right ADC Capacity — or Too Much?

In Songdo, on the reclaimed waterfront west of Seoul, a 202,000-square-metre construction site is becoming the most expensive single statement Kore...

June 19, 2026 | Analysis

Stay Connected